Urcosimod, formerly OK-101, is a lipid conjugated chemerin peptide agonist targeting the ChemR23 G-protein coupled receptor found on immune and neuronal cells. Developed to enhance ocular ...

(RTTNews) - OKYO Pharma Limited (OKYO) has announced that its lead drug candidate, OK-101, has officially been assigned the United States Adopted Name or USAN "Urcosimod." This name reflects the ...

This naming milestone underscores the progress of urcosimod (OK-101) in its clinical development program. Gary S. Jacob, Ph.D., Chief Executive Officer of Okyo Pharma, commented: “We are ...

Notably, there is no FDA approved drug to treat this debilitating condition. About Urcosimod (Formerly called OK-101) Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein ...

About Urcosimod (Formerly called OK-101)Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye ...

This naming milestone underscores the progress of urcosimod (OK-101) in its clinical development program. Gary S. Jacob, Ph.D., Chief Executive Officer of Okyo Pharma, commented: “We are thrilled to ...